Apolipoprotein A1 and Transferrin as Biomarkers in Ovarian Cancer Diagnostics
Authors:
- Simona DoninaSDSimona Donina
- 1 January 2010
- journal article
- Published by Walter de Gruyter GmbH in Acta Chirurgica Latviensis
- Vol. 10 (2) , 16-20
Abstract
Apolipoprotein A1 and Transferrin as Biomarkers in Ovarian Cancer Diagnostics: Introduction. Advanced technologies such as matrix assisted laser desorption/ionization and surface enhanced laser desorption/ionization mass spectrometry has introduced promising insights into ovarian cancer detection. Several highly sensitive and specific protein peaks have been identified that discriminates ovarian cancer patients from patients with benign ovarian tumors and controls. Aim of the Study. Objective of this study is to evaluate diagnostic accuracy each individual marker and combined serum biomarker assay consisting of apolipoprotein A1, transferrin and Ca125. Materials and methods. A case-control study consisted of 99 women - 37 patients with ovarian cancer, 31 patients with benign ovarian diseases, and 31 age-matched healthy controls. Apolipoprotein A1 and transferrin was measured in sera using immunological turbidimetric assay. Tumor marker CA125 was analyzed by standard enzyme-labeled chemiluminescent immunometric assay. To compare the difference between variables in the study groups, ANOVA test was performed and for correlation Pearson's correlation analysis applied. Sensitivity and specificity of the diagnostic tests was calculated using statistical program Vassarstat. Results. Serum apolipoprotein A1 and transferrin were down regulated, controversially to Ca125, which was up regulated among ovarian cancer patients. Negative correlation between transferrin and Ca 125 (p<0.00), apolipoprotein A1 and Ca 125 (p<0.00) and positive correlation between transferrin and apolipoprotein A1 (p 21U/ml and apolipoprotein A1 ≤ 139.1 mg/dl or transferrin ≤ 2.3 g/l), yielded test specificity of 96.7%. Addition of apolipoprotein A1 to Ca125 improved test sensitivity up to 94.5% maintaining high sensitivity at the same time 91.1%, respectively, when discriminating controls from ovarian cancer patients. Biomarker test consisting of apolipoprotein A1, transferrin and Ca125 had high specificity at unacceptable sensitivity. Conclusions. Combined biomarker tests discovered using advanced technologies can aid more accurate ovarian cancer detection. Use of apolipoprotein A1 in combination with Ca125 at distinct thresholds can improve ovarian cancer detection.Keywords
This publication has 17 references indexed in Scilit:
- Validation of serum biomarkers for detection of early-stage ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2009
- Serum Proteomics Using Mass Spectrometry2009
- Evaluation of Apolipoprotein A1 and Posttranslationally Modified Forms of Transthyretin as Biomarkers for Ovarian Cancer Detection in an Independent Study PopulationCancer Epidemiology, Biomarkers & Prevention, 2006
- Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditionsBiochemistry (Moscow), 2006
- Characterization of serum biomarkers for detection of early stage ovarian cancerProteomics, 2005
- Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian CancerCancer Research, 2004
- Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in UrineThe American Journal of Pathology, 2001
- Recent trends in protein biochip technologyPharmacogenomics, 2000
- Is there a place for screening in ovarian cancer?European Journal of Obstetrics & Gynecology and Reproductive Biology, 1999
- A QUANTITATIVE THEORY OF THE PRECIPITIN REACTIONJournal of Experimental Medicine, 1935